Long-term erythropoietin therapy does not affect metalloproteinases and their inhibitor levels, oxidative stress and inflammation in hemodialyzed patients.

Abstract

BACKGROUND:

Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) play an important role in the atherosclerosis. Recombinant human erythropoietin (EPO) has become widely used to treat anemic hemodialyzed (HD) patients; however, an increased mortality has been reported for HD patients with cardiovascular disease when randomly assigned to normal hematocrit by EPO. Therefore, we conducted a study examining the effect of EPO on MMPs/TIMPs system, oxidative stress and inflammation in these patients.

METHODS:

Assessment of MMP-2, MMP-9, TIMP-1 and TIMP-2 were performed in 20 stable HD patients and 15 healthy controls. Additionally, the effects of EPO on malondialdehyde (MDA)--a marker of SOX and C-reactive protein (CRP) levels--as a marker of inflammation were also investigated. Of the 20 patients, 10 were receiving EPO therapy [HD-EPO(+)] for 12 months or more and 10 were not receiving EPO therapy [HD-EPO(-)]. Both groups were not receiving iron supplementation.

RESULTS:

All parameters, with the exception of MMP-9, were lower in the healthy subjects compared with the HD subjects, irrespective of EPO administration. There was no difference in MMPs/TIMPs system, MDA and C-reactive levels between HD-EPO(+) and HD-EPO(-) patients.

CONCLUSION:

Erythropoietin therapy did not influence MMPs/TIMPs system, inflammation, or SOX in a low-risk HD patient population, in the absence of concomitant iron supplementation and mean Hg levels within target.

• Authors: Krystyna Pawlak, Dariusz Pawlak, Michal Mysliwiec
• Journal: American journal of nephrology (Am J Nephrol) Vol. 27 Issue 3 Pg. 221-5 ( 2007) ISSN: 1421-9670 [Electronic] Switzerland
• PMID: 17384500 (Publication Type: Journal Article)
• Copyright: 2007 S. Karger AG, Basel

Chemical References

• Tissue Inhibitor of Metalloproteinases
• Erythropoietin
• Malondialdehyde
• C-Reactive Protein
• Metalloproteases

Topics

• Adult
• Aged
• Anemia (drug therapy)
• C-Reactive Protein (metabolism)
• Case-Control Studies
• Erythropoietin (administration & dosage, adverse effects)
• Female
• Humans
• Male
• Malondialdehyde (blood)
• Metalloproteases (blood, drug effects)
• Middle Aged
• Oxidative Stress (drug effects)
• Renal Dialysis (adverse effects)
• Tissue Inhibitor of Metalloproteinases (blood, drug effects)
• Uremia (therapy)